NVCR News and Press, NovoCure Limited From 01/08/20

Shares of NovoCure (NASDAQ: NVCR) , which makes devices for treating cancerous solid tumors with electric fields, rocketed 152% higher last year, according to data from S&P Global Market Intelligence . That sizzling performance makes it one of last year's hottest healthcare stocks . Fo...

NovoCure (NVCR) is an innovative medical device company that is developing the fourth modality in cancer treatment. I rate NovoCure a buy . As the lead and only developer of Tumor Treating Field (TTField), the company has the potential to gain a significant share of the vast cancer treatm...

NovoCure ( NVCR ) is a name which I have followed with great interest, with the latest update dating back to November of 2018 as I concluded that it was an "interesting cure for the portfolio." 2019 has proven to be a great year with shares at some point having tripled from the 2018 levels...

Shares of Novocure (NASDAQ: NVCR) are down 9.3% at 3:37 p.m. EST, after being down down as much as 11.5% earlier in the day, after an analyst at Evercore ISI downgraded the medical-device maker to "in line." Considering how much Novocure's stock price has increased lately, the downgrade sho...

Baxter International (NYSE: BAX ) upgraded to Outperform with a $94 (12% upside) price target at Evercore ISI. Shares up  1%  premarket. More news on: Baxter International Inc., Henry Schein, Inc., Medtronic plc, Healthcare stocks news, Stocks on the move, , Read more ...

Novocure (NASDAQ: NVCR) will participate in the 38 th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. He is scheduled to prese...

NovoCure Limited (NVCR) is a ~$7.9 billion market capitalization oncology device company that provides patients with a new cancer treatment based on alternating electric field technology. The company's lead product is based on the research work of founder Yoram Palti that such electric fields,...

Larry Culp is a Builder of Corporations, Not a Caretaker We've all heard the nostrum "The best defense is a good offense". The best way for General Electric (GE) to dig out of its liabilities is to change the growth profile and boost cash flow. The opportunity to gather revenue-generating ...

SANTA CLARA, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that Jeri Hilleman has joined its Board of Directors, effective imme...

Shares of NovoCure  (NASDAQ: NVCR) , which makes devices for treating cancerous solid tumors with electric fields, rocketed 28.7% last month, according to data from  S&P Global Market Intelligence . For context, the S&P 500 returned 3.6% in November. The  healthc...